Gefticip contains Gefitinib 250 mg, a targeted therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). It belongs to a class of medications known as EGFR (epidermal growth factor receptor) inhibitors. By blocking EGFR, Gefticip helps stop the growth and spread of cancer cells that depend on this receptor for survival and proliferation.

• Effective in treating locally advanced or metastatic NSCLC

• Works by inhibiting cancer cell growth at the molecular level

• Oral therapy that can be taken at home

• Especially useful for patients with EGFR mutation-positive tumors

• Take one tablet (250 mg) orally once daily, with or without food

• Swallow whole with water; do not crush or chew

• Take the dose at the same time each day for best results

• Follow your oncologist’s instructions carefully

• Strength: 250 mg Gefitinib per tablet

• Route: Oral

• Frequency: Once daily

• Duration: As prescribed based on disease progression and tolerance

• Use only under strict medical supervision

• Liver and kidney functions should be regularly monitored

• Not recommended during pregnancy or breastfeeding

• Avoid use with CYP3A4 inducers/inhibitors unless advised by a doctor

• Inform your doctor of all current medications and supplements

• Diarrhea, skin rash, acne

• Nausea, vomiting, and weakness

• Rare but serious effects: Interstitial lung disease, liver toxicity

• Contact your doctor immediately if you experience breathing difficulty, jaundice, or severe skin reactions